![](https://cc-tdi.org/wp-content/uploads/2018/11/Clear-Cell-Sarcoma-BigData-300x214.jpg)
![](https://cc-tdi.org/wp-content/uploads/2018/11/Clear-Cell-Sarcoma-BigData-300x214.jpg)
![Expanding Chemical Space](https://cc-tdi.org/wp-content/uploads/2018/11/Screen-Shot-2018-12-03-at-11.59.08-AM-300x185.png)
A Radiation Synthetic Combination for Osteosarcoma Local Control: $100,000 annually
Be the sponsor of this project! Osteosarcoma is a disease for which local control can be critical: for tumors in a limb, local control permits
![](https://cc-tdi.org/wp-content/uploads/2018/11/Curefast-300x200.jpg)
CureFast: Creating a Legacy by Accelerating Childhood Cancer Research: $156,000 annually
Be the sponsor of this project! One in 5 children with cancer will not survive. We propose to address gaps in basic and translational research
![](https://cc-tdi.org/wp-content/uploads/2018/11/Marizomib-in-Medulloblastoma-300x288.jpg)
Marizomib in Medulloblastoma: $240,000 over 2 years
The goal of this preclinical study is to validate marizomib as a treatment for medulloblastoma.
![](https://cc-tdi.org/wp-content/uploads/2018/11/Dupixent-as-an-anti-metastasis-agent-1024x793-1-300x232.jpg)
Dupixent as an anti-metastasis agent for Rhabdomyosarcoma: $240,000 over 2 years
Be the sponsor of this project! What if an FDA-approved dermatitis and asthma medicine could stop rhabdomyosarcoma metastasis? The major goal of this project is
![](https://cc-tdi.org/wp-content/uploads/2018/11/The-IL13RA2-HAS2-axis-300x113.png)
The IL13RA2-HAS2 axis as therapeutic co-targets in DIPG: $249,000 over 2 years
Be the sponsor for this project! We have investigated presence of the IL13RA2 protein in DIPG, and we have shown there is 13 times higher
![](https://cc-tdi.org/wp-content/uploads/2018/11/Clear-Cell-Sarcoma-BigData-300x214.jpg)
![Expanding Chemical Space](https://cc-tdi.org/wp-content/uploads/2018/11/Screen-Shot-2018-12-03-at-11.59.08-AM-300x185.png)
A Radiation Synthetic Combination for Osteosarcoma Local Control: $100,000 annually
Be the sponsor of this project! Osteosarcoma is a disease for which local control can be critical: for tumors in a limb, local control permits
![](https://cc-tdi.org/wp-content/uploads/2018/11/Curefast-300x200.jpg)
CureFast: Creating a Legacy by Accelerating Childhood Cancer Research: $156,000 annually
Be the sponsor of this project! One in 5 children with cancer will not survive. We propose to address gaps in basic and translational research
![](https://cc-tdi.org/wp-content/uploads/2018/11/Marizomib-in-Medulloblastoma-300x288.jpg)
Marizomib in Medulloblastoma: $240,000 over 2 years
The goal of this preclinical study is to validate marizomib as a treatment for medulloblastoma.
![](https://cc-tdi.org/wp-content/uploads/2018/11/Dupixent-as-an-anti-metastasis-agent-1024x793-1-300x232.jpg)
Dupixent as an anti-metastasis agent for Rhabdomyosarcoma: $240,000 over 2 years
Be the sponsor of this project! What if an FDA-approved dermatitis and asthma medicine could stop rhabdomyosarcoma metastasis? The major goal of this project is
![](https://cc-tdi.org/wp-content/uploads/2018/11/The-IL13RA2-HAS2-axis-300x113.png)
The IL13RA2-HAS2 axis as therapeutic co-targets in DIPG: $249,000 over 2 years
Be the sponsor for this project! We have investigated presence of the IL13RA2 protein in DIPG, and we have shown there is 13 times higher